



Bibliography Reference List

Platelia *Aspergillus* Ag Assay

275 references published from 1998 to 2024

Since its launch in 1998, the Platelia *Aspergillus* Ag Assay has been the subject of a rich body of scientific and clinical research. This list presents the available articles and posters pertaining to the assay from its commercial launch up to July 2024.

The 275 references were found through Bio-Rad's Literature Search Process, an internal procedure that follows the guidelines set by the European Regulations (EU) 2017/746, using the Embase and MEDLINE databases.

The views and opinions expressed in these articles are those of the authors. Please note that **some articles focus on particular use cases—such as specific specimens, specific patient populations and different result interpretation rules—which are not validated or claimed by Bio-Rad** in the current IFU for Platelia *Aspergillus* Ag. **These use cases should therefore be considered with caution.**

This bibliography reference list is for informational purposes only and is not intended to provide medical advice or diagnosis. Because of intellectual property protections, Bio-Rad is unable to provide direct access to the articles in this reference list.

Articles

1. Acet-Öztürk NA et al. (2024). Impact of posaconazole prophylaxis and antifungal treatment on BAL GM performance in hematology malignancy patients with febrile neutropenia: a real-life experience. *European Journal of Clinical Microbiology & Infectious Diseases* 43, 33–43.
2. Aerts R et al. (2024). Microbiological diagnosis of pulmonary *Aspergillus* infections. *Seminars in Respiratory and Critical Care Medicine* 45, 021–031.
3. Ajayababu A et al. (2024). Effect of volume of instillate on the diagnostic utility of bronchoalveolar lavage galactomannan in patients with suspected chronic pulmonary aspergillosis—A pilot study. *Mycoses* 67, e13695.
4. Albert E et al. (2024). Comparative performance of the Platelia *Aspergillus* antigen and *Aspergillus* galactomannan antigen Virclia Monotest immunoassays in serum and lower respiratory tract specimens: a “real-life” experience. *Microbiology Spectrum* 12, e03910-23.
5. Boyer J et al. (2024). Performance of the clarus *Aspergillus* galactomannan enzyme immunoassay prototype for the diagnosis of invasive pulmonary aspergillosis in serum. *Mycoses* 67, e13756.
6. Chatterjee K et al. (2024). Utility of galactomannan diagnostic assay in rhino-orbito-cerebral mycosis in COVID-19 patients. *Indian Journal of Medical Microbiology* 48, 100557.
7. Chun JY et al. (2024). Performance of the galactomannan test for the diagnosis of invasive pulmonary aspergillosis using non-invasive proximal airway samples. *Journal of Infection* 88, 106159.
8. Conterno LO et al. (2024). Six-year experience with GM test in hematological patients in a public Brazilian tertiary hospital. *The Brazilian Journal of Infectious Diseases* 28, 103718.
9. Devillers E et al. (2024). Comparison of different lateral flow assays on bronchoalveolar lavage fluid for invasive aspergillosis screening in non-hematological patients. *Journal of Medical Mycology* 34, 101481.
10. van Grootveld R et al. (2024). Prospective and systematic screening for invasive aspergillosis in the ICU during the COVID-19 pandemic, a proof of principle for future pandemics. *Medical Mycology* 62, myae028.
11. Keche A et al. (2024). Galactomannan antigen assay for the diagnosis of invasive aspergillosis: a study from a tertiary care hospital of central India. *Journal of Pure and Applied Microbiology* 18, 878–885.
12. Wang H et al. (2024). Performance of rapid on-site evaluation of touch imprints of bronchoscopic biopsies or lung tissue biopsies for the diagnosis of invasive pulmonary filamentous fungi infections in non-neutropenic patients. *Journal of Clinical Microbiology* 62, e0047924.

13. Wang W et al. (2024). Time-resolved fluoroimmunoassay for *Aspergillus* detection based on anti-galactomannan monoclonal antibody from stable cell line. *Analytical Biochemistry* 689, 115494.
14. Aerts R et al. (2023). Implementation of lateral flow assays for the diagnosis of invasive aspergillosis in European hospitals: a survey from Belgium and a literature review of test performances in different patient populations. *Mycopathologia* 188, 655–665.
15. Alhan O et al. (2023). Diagnostic efficacy of *Aspergillus* galactomannan lateral flow assay in patients with hematological malignancies: a prospective multicenter study. *Mycopathologia* 188, 643–653.
16. Buil JB et al. (2023). Retrospective multicenter evaluation of the VirClia galactomannan antigen assay for the diagnosis of pulmonary aspergillosis with bronchoalveolar lavage fluid samples from patients with hematological disease. *Journal of Clinical Microbiology* 61, e0004423.
17. Chong E et al. (2023). False-positive *Aspergillus* galactomannan immunoassay in the glucose component of total parenteral nutrition products. *Microbiology Spectrum* 11, e0167323.
18. Chowdhury M et al. (2023). The utility of galactomannan and polymerase chain reaction assays in bronchoalveolar lavage for diagnosis of chronic pulmonary aspergillosis. *Mycopathologia*. 188, 1041–1053.
19. Das S et al. (2023). Diagnostic utility of galactomannan enzyme immunoassay in invasive aspergillosis in pediatric patients with hematological malignancy. *Mycopathologia* 188, 1055–1063.
20. Dichtl K et al. (2023). Performance of galactomannan testing from endotracheal aspirate to guide bronchoalveolar lavage in the diagnosis of invasive aspergillosis. *Infection* 51, 769–774.
21. Dubler Simon et al. (2023). Impact of invasive pulmonary aspergillosis in critically ill surgical patients with or without solid organ transplantation. *Journal of Clinical Medicine* 12, 3282.
22. Estella Á et al. (2023). Microbiological diagnosis of pulmonary invasive aspergillosis in critically ill patients with severe SARS-CoV-2 pneumonia: a bronchoalveolar study. *Annals of Clinical Microbiology and Antimicrobials* 22, 90. (Erratum in: (2023) *Annals of Clinical Microbiology and Antimicrobials* 9, 100).
23. Lass-Flörl C et al. (2023). A laboratory-based study on multiple biomarker testing in the diagnosis of COVID-19-associated pulmonary aspergillosis (CAPA): real-life data. *Diagnostics* 13,114.
24. Mah J et al. (2023). Superior accuracy of *Aspergillus* plasma cell-free DNA polymerase chain reaction over serum galactomannan for the diagnosis of invasive aspergillosis. *Clinical Infectious Diseases* 77, 1282–1290.
25. de Oliveira VF et al. (2023). Sensitivity of antigen, serology, and microbiology assays for diagnosis of the subtypes of chronic pulmonary aspergillosis at a teaching hospital in São Paulo, Brazil. *American Journal of Tropical Medicine and Hygiene* 108, 22–26.
26. de Oliveira VF et al. (2023). Systematic review and meta-analysis of galactomannan antigen testing in serum and bronchoalveolar lavage for the diagnosis of chronic pulmonary aspergillosis: defining a cutoff. *European Journal of Clinical Microbiology & Infectious Diseases* 42, 1047–1054.
27. Pavone P et al. (2023). Active screening of COVID-19-associated pulmonary aspergillosis with serum beta-glucan and endotracheal aspirates galactomannan and fungal culture. *Mycoses* 66, 219–225.
28. Ren W et al. (2023). Serum cytokine biomarkers for use in diagnosing pulmonary tuberculosis versus chronic pulmonary aspergillosis. *Infection and Drug Resistance* 16, 2217–222.
29. Roiz-Mesones MP et al. (2023). Evaluation of the EUROIMMUN *Aspergillus* antigen immunoenzyme assay in serum and bronchoalveolar lavage fluid samples. *Enfermedades Infecciosas y Microbiología Clínica* 41, 176–180.
30. Rothe K et al. (2023). Galactomannan-antigen testing from non-directed bronchial lavage for rapid detection of invasive pulmonary aspergillosis in critically ill patients: a proof-of-concept study. *Diagnostics* 13, 1190.
31. Sabbah R et al. (2023). Utility of galactomannan screening for early detection of invasive aspergillosis in high-risk hemato-oncology patients. *Acta Haematologica* 146, 358–365.
32. Samantaray Subhashree et al. (2023). Invasive cerebral aspergillosis in non-neutropenic patients: a case series from Western India. *Journal of Medical Mycology* 33, 101380.
33. Sharad N et al. (2023). Therapeutic drug monitoring of voriconazole in children with hematologic malignancy and invasive fungal infections: an RCT study from a tertiary care centre in India. *Cardiovascular & Hematological Disorders-Drug Targets* 23, 285–292.
34. Shi Y et al. (2023). Metagenomic next-generation sequencing for detecting aspergillosis pneumonia in immunocompromised patients: a retrospective study. *Frontiers in Cellular and Infection Microbiology* 13, 1209724.
35. Shu F et al. (2023). Evaluation of the yeast phase-specific monoclonal antibody 4D1 and *Galanthus nivalis* agglutinin sandwich ELISA to detect *Talaromyces marneffeii* antigen in human urine. *Frontiers in Cellular and Infection Microbiology* 13, 1163868.
36. Zhou L et al. (2023). Diagnostic performance of noncultural methods for central nervous system aspergillosis. *Mycoses* 66, 308–316.

37. Zhou X et al. (2023). Risk factors and the value of microbiological examinations of COVID-19 associated pulmonary aspergillosis in critically ill patients in intensive care unit: the appropriate microbiological examinations are crucial for the timely diagnosis of CAPA. *Frontiers in Cellular and Infection Microbiology* 13, 1287496.
38. Zhu N et al. (2023). Performance of mNGS in bronchoalveolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in non-neutropenic patients. *Frontiers in Cellular and Infection Microbiology* 13, 1271853.
39. Aerts R et al. (2022). Performance of the JF5-based galactomannoprotein EIA compared to the lateral flow device and the galactomannan EIA in serum and bronchoalveolar lavage fluid *Journal of Clinical Microbiology* 60, e0094822.
40. de Almeida JN et al. (2022). COVID-19-associated aspergillosis in a Brazilian referral centre: diagnosis, risk factors and outcomes. *Mycoses* 65, 449–457.
41. Bellanger AP et al. (2022). Investigation of the value of precipitins in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patients with a positive marker for *Aspergillus* species. *Medical Mycology* 60, myac031.
42. Bernardi RM et al. (2022). Evaluation of the diagnostic accuracy of galactomannan from the bronchoalveolar lavage fluid of patients with suspected invasive pulmonary aspergillosis. *Revista Iberoamericana de Micología* 39, 31–35.
43. Boyanova L (2022). Molecular and microbiological approaches for rapid etiological diagnosis of systemic mycoses. *Problems of Infectious and Parasitic Diseases* 49, 35–42.
44. Caggiano G et al. (2022). Tendency in pulmonary aspergillosis investigation during the COVID-19 era: What is changing? *International Journal of Environmental Research and Public Health* 19, 7079.
45. Calero AL et al. (2022). Comparison of the performance of two galactomannan detection tests: Platelia *Aspergillus* Ag and *Aspergillus* galactomannan Ag Virclia Monotest. *Microbiology Spectrum* 10, e02626-21.
46. Dargenio VN et al. (2022). An unexpected guest in a patient with ulcerative colitis. *Gastroenterology* 163, e1–e2.
47. Egger M et al. (2022). Performance of the Euroimmun *Aspergillus* Antigen ELISA for the diagnosis of invasive pulmonary aspergillosis in bronchoalveolar lavage fluid. *Journal of Clinical Microbiology* 60, e0021522.
48. Forster J et al. (2022). β -1,3-D-glucan and galactomannan as biomarkers for the detection of invasive *Geotrichum* and *Magnusiomyces* infections: a retrospective evaluation. *Journal of Clinical Microbiology* 60, e0160721.
49. Giusiano G et al. (2022). Usefulness of Sōna *Aspergillus* Galactomannan LFA with digital readout as diagnostic and as screening tool of COVID-19 associated pulmonary aspergillosis in critically ill patients. Data from a multicenter prospective study performed in Argentina. *Medical Mycology* 60, myac026.
50. Guo Y and Li J (2022). Sandwich-type homogeneous chemiluminescence immunoassay based on nanoparticle toward detection of *Aspergillus* galactomannan antigen. *Talanta* 243, 123392.
51. Hashim Z et al. (2022). Practice guidelines for the diagnosis of COVID-19-associated pulmonary aspergillosis in an intensive care setting. *Journal of Intensive Care Medicine* 37, 985–997.
52. Hernández-Solí A et al. (2022). Pulmonary aspergilloma in immunocompromised patients in a respiratory care unit. *Journal of Infection in Developing Countries* 16, 564–569.
53. Hsiao H-H et al. (2022). Comparison of a novel lateral-flow device to galactomannan assay at different time periods for detections of invasive aspergillosis. *Journal of the Formosan Medical Association* 121, 2123–2129.
54. McKinney WP et al. (2022). Performance of the IMMY® and OLM® lateral flow assays for *Aspergillus* galactomannan compared to fungal culture and Platelia™ galactomannan enzyme immuno-assay. *New Zealand Journal of Medical Laboratory Science* 76, 27–31.
55. Melchers M et al. (2022). A 67-year-old male patient with COVID-19 with worsening respiratory function and acute kidney failure. *Chest* 161, e5–e11.
56. Swain S et al. (2022). COVID-19-associated subacute invasive pulmonary aspergillosis. *Mycoses* 65, 57–64.
57. Tschopp J et al. (2022). High false-positive rate of (1,3)- β -D-glucan in onco-hematological patients receiving immunoglobulins and therapeutic antibodies. *Clinical Infectious Diseases* 75, 330–333.
58. Xiao W et al. (2022). Existing tests vs. novel non-invasive assays for detection of invasive aspergillosis in patients with respiratory diseases. *Chinese Medical Journal* 135, 1545–1554.
59. Bellanger A-P et al. (2021). Investigating the impact of posaconazole prophylaxis on systematic fungal screening using galactomannan antigen, *Aspergillus fumigatus* qPCR, and Mucorales qPCR. *Journal of Medical Mycology* 31, 101117.
60. Busca A et al. (2021). Management of invasive fungal infections in patients undergoing allogeneic hematopoietic stem cell transplantation: the Turin experience. *Frontiers in Cellular and Infection Microbiology* 11, 805514.
61. Chiu Y-Y et al. (2021). A rare patient with primary endogenous *Aspergillus* endophthalmitis. *Journal of Microbiology, Immunology and Infection* 54, 538–539.

62. Ergün M et al. (2021). *Aspergillus* test profiles and mortality in critically ill COVID-19 patients. *Journal of Clinical Microbiology* 59, e0122921.
63. Ghelfenstein-Ferreira T et al. (2021). Recovery of a triazole-resistant *Aspergillus fumigatus* in respiratory specimen of COVID-19 patient in ICU – A case report. *Medical Mycology Case Reports* 31, 15–18.
64. Haran A et al. (2021). False-positive galactomannan antigen testing in pulmonary nocardiosis. *Medical Mycology* 59, 206–209.
65. Hill JA et al. (2021). Liquid biopsy for invasive mold infections in hematopoietic cell transplant recipients with pneumonia through next-generation sequencing of microbial cell-free DNA in plasma. *Clinical Infectious Diseases* 73, e3876–e3883.
66. Hsu AJ et al. (2021). Challenges with utilizing the 1,3-Beta-D-glucan and galactomannan assays to diagnose invasive mold infections in immunocompromised children. *Journal of Clinical Microbiology* 59, e03276-20.
67. Huang L et al. (2021). Diagnostic value of galactomannan test in non-immunocompromised critically ill patients with influenza-associated aspergillosis: data from three consecutive influenza seasons. *European Journal of Clinical Microbiology and Infectious Diseases* 40, 1899–1907.
68. Lass-Flörl C et al. (2021). Serology anno 2021—fungal infections: from invasive to chronic. *Clinical Microbiology and Infection* 27, 1230–1241.
69. Mercier T et al. (2021). Defining galactomannan positivity in the updated EORTC/MSGERC consensus definitions of invasive fungal diseases. *Clinical Infectious Diseases* 72, S89–S94.
70. Mercier T et al. (2021). Prospective evaluation of the turbidimetric β -D-glucan assay and 2 lateral flow assays on serum in invasive aspergillosis. *Clinical Infectious Diseases* 72, 1577–1584.
71. Niyazi D et al. (2021). Invasive pulmonary aspergillosis in patients with haematological malignancies and hematopoietic stem cell transplantation: a single-center study. *Folia medica* 63, 941–947.
72. Oliva A et al. (2021). Comparison of clinical features and outcomes in COVID-19 and influenza pneumonia patients requiring intensive care unit admission. *Infection* 49, 965–975.
73. Roman-Montes CM et al. (2021). Accuracy of galactomannan testing on tracheal aspirates in COVID-19-associated pulmonary aspergillosis. *Mycoses* 64, 364–371.
74. Rothe K et al. (2021). Clinical and microbiological features and outcomes of mucormycosis in critically ill patients. *International Journal of Infectious Diseases* 109, 142–147.
75. Schroeder I et al. (2021). Digestive enzymes of fungal origin as a relevant cause of false positive *Aspergillus* antigen testing in intensive care unit patients. *Infection* 49, 241–248.
76. Segrelles-Calvo G et al. (2021). Prevalence of opportunistic invasive aspergillosis in COVID-19 patients with severe pneumonia. *Mycoses* 64, 144–151.
77. Singh S et al. (2021). Comparative accuracy of 1,3 beta-D glucan and galactomannan for diagnosis of invasive fungal infections in pediatric patients: a systematic review with meta-analysis. *Medical Mycology* 59, 139–148.
78. Trujillo H et al. (2021). Invasive pulmonary aspergillosis associated with COVID-19 in a kidney transplant recipient. *Transplant Infectious Disease* 23, e13501.
79. Wei H et al. (2021). The values of (1,3)- β -D-glucan and galactomannan in cases of invasive fungal rhinosinusitis. *American Journal of Otolaryngology - Head and Neck Medicine and Surgery* 42, 102871.
80. Wu Z et al. (2021). Diagnostic value of galactomannan in serum and bronchoalveolar lavage fluid for invasive pulmonary aspergillosis in non-neutropenic patients. *Diagnostic Microbiology and Infectious Disease* 99, 115274.
81. Ahamefula Osibe D et al. (2020). Cell wall polysaccharides from pathogenic fungi for diagnosis of fungal infectious disease. *Mycoses* 63, 644–652.
82. Bougnoux M-E et al. (2020). Impact of intravenous and subcutaneous immunoglobulins on false positivity of galactomannan and β -D-glucan antigenaemia and detection of circulating *Aspergillus fumigatus* DNA. *Clinical Microbiology and Infection* 26, 1101–1102.
83. Lee S-I et al. (2020). Usefulness of ICU criteria for diagnosis of invasive pulmonary aspergillosis in nonhematologic critically ill patients. *Medical Mycology* 58, 275–281.
84. Li X et al. (2020) Evaluation of quantitative real-time PCR and *Platelia* galactomannan assays for the diagnosis of disseminated *Talaromyces marneffe* infection. *Medical Mycology* 58, 181-186.
85. Liu W-D et al. (2020). False-positive *Aspergillus* galactomannan immunoassays associated with intravenous human immunoglobulin administration. *Clinical Microbiology and Infection* 26, 1555.e9-1555.e14.
86. Mercier T et al. (2020). Point of care *Aspergillus* testing in intensive care patients. *Critical Care* 24, 642.
87. Nasir N et al. (2020). COVID-19-associated pulmonary aspergillosis (CAPA) in patients admitted with severe COVID-19 pneumonia: an observational study from Pakistan. *Mycoses* 63, 766–770.
88. Nyga R et al. (2020). Invasive tracheobronchial aspergillosis in critically ill patients with severe influenza. A clinical trial. *American Journal of Respiratory and Critical Care Medicine* 202, 708–716.
89. Patel R et al. (2020). A unique case of disseminated histoplasmosis misdiagnosed as invasive aspergillosis. *Chest* 158, A367–A368.

90. Sarwar M et al. (2020). Evaluation of galactomannan and beta-d-glucan assays for the diagnosis of invasive aspergillosis in clinically suspected cases. *Journal of the Pakistan Medical Association* 70, 442-446.
91. Schein F et al. (2020). Fatal aspergillosis complicating severe SARS-CoV-2 infection: a case report. *Journal de Mycologie Médicale* 30, 101039.
92. Taton O et al. (2020). Role of the bronchoalveolar lavage in noncritically ill patients during the SARS-CoV-2 epidemic. *Pulmonary Medicine* 2020, 9012187.
93. Dichtl K et al. (2019). Evaluation of a novel *Aspergillus* antigen enzyme-linked immunosorbent assay. *Journal of Clinical Microbiology* 57, e00136-19.
94. Jenks JD et al. (2019). Bronchoalveolar lavage *Aspergillus* galactomannan lateral flow assay versus *Aspergillus*-specific lateral flow device test for diagnosis of invasive pulmonary aspergillosis in patients with hematological malignancies. *Journal of Infection* 78, 249–259.
95. Jenks JD et al. (2019). Point-of-care diagnosis of invasive aspergillosis in non-neutropenic patients: *Aspergillus* galactomannan lateral flow assay versus *Aspergillus*-specific lateral flow device test in bronchoalveolar lavage. *Mycoses* 62, 230–236.
96. Khaithir TMN et al. (2019). Epidemiology, laboratory detection and distribution of *Aspergillus* species from clinical samples in a tertiary medical centre from Malaysia. *International Medical Journal* 26, 483–486.
97. Ortiz-Brizuela E et al. (2019). False-positive results in the galactomannan Platelia™ *Aspergillus* assay with generic piperacillin/tazobactam. *Revista Iberoamericana de Micología* 36, 51–52.
98. Takazono T et al. (2019). Clinical features and cause analysis of false positive results of *Aspergillus* galactomannan assay in pulmonary cryptococcosis patients. *European Journal of Clinical Microbiology and Infectious Diseases* 38, 735–741.
99. Wang X et al. (2019). Utility of serum galactomannan antigen testing combined with chest computed tomography for early diagnosis of invasive pulmonary aspergillosis in patients with hematological malignancies with febrile neutropenia after antifungal drug treatment. *Journal of International Medical Research* 47, 783–790.
100. Abe Y et al. (2018). Prevalence and clinical characteristics of false-positive *Aspergillus* galactomannan test in healthy subjects and patients with hematologic malignancies. *Blood* 132 (Supplement 1), 2408.
101. Moura S et al. (2018). Invasive pulmonary aspergillosis: current diagnostic methodologies and a new molecular approach. *European Journal of Clinical Microbiology and Infectious Diseases* 37, 1393–1403.
102. Roohani A et al. (2018). Comparing the profile of respiratory fungal pathogens amongst immunocompetent and immunocompromised hosts, their susceptibility pattern and correlation of various opportunistic respiratory fungal infections and their progression in relation to the CD4+T-cell counts. *Indian Journal of Medical Microbiology* 36, 408–415.
103. Singh S et al. (2018). Evaluation of biomarkers: galactomannan and 1,3-beta-D-glucan assay for the diagnosis of invasive fungal infections in immunocompromised patients from a tertiary care centre. *Indian Journal of Medical Microbiology* 36, 557–563.
104. Vrioni G et al. (2018). Use of galactomannan antigen and *Aspergillus* DNA real-time polymerase chain reaction as routine methods for invasive aspergillosis in immunosuppressed children in Greece. *Clinical Therapeutics*. 40, 918-924.e2.
105. Yoshimura K et al. (2018). Utility of serum *Aspergillus*-galactomannan antigen to evaluate the risk of severe acute exacerbation in chronic obstructive pulmonary disease. *PLoS ONE* 13, e0198479.
106. Alanio A et al. (2017). Circulating *Aspergillus fumigatus* DNA is quantitatively correlated to galactomannan in serum. *Frontiers in Microbiology* 8, 2040.
107. Kaur R et al. (2017). Fungal opportunistic pneumonias in HIV/AIDS patients: an Indian tertiary care experience. *Journal of Clinical and Diagnostic Research* 11, DC14–DC19.
108. Ramanan P et al. (2017). Laboratory diagnostics for fungal infections: a review of current and future diagnostic assays. *Clinics in Chest Medicine* 38, 535–554.
109. Weinbergerova B et al. (2017). Serological approaches. *Methods in Molecular Biology* 1508, 209–221.
110. White PL et al. (2017). An evaluation of the performance of the Dynamiker® Fungus (1-3)-β-D-Glucan Assay to assist in the diagnosis of invasive aspergillosis, invasive candidiasis and *Pneumocystis pneumonia*. *Medical Mycology* 55, 843–850.
111. Badiee P et al. (2016). Non-invasive methods to diagnose fungal infections in pediatric patients with hematologic disorders. *Jundishapur Journal of Microbiology* 9, e41573.
112. Boch T et al. (2016). Direct comparison of galactomannan performance in concurrent serum and bronchoalveolar lavage samples in immunocompromised patients at risk for invasive pulmonary aspergillosis. *Mycoses* 59, 80–85.
113. Erdmann J-H et al. (2016). Anti-*Aspergillus* immunoglobulin-G testing in serum of hematopoietic stem cell transplant recipients. *Transplant Infectious Disease* 18, 354–360.
114. Knoth H et al. (2016). In-vitro detection of mannan and galactomannan in components of total parenteral nutrition (TPN). *Pharmazie* 71, 238–242.

115. Li M-C et al. (2016). Diagnostic role of an oligonucleotide array in a heart transplantation patient with invasive pulmonary aspergillosis. *Journal of Microbiology, Immunology and Infection* 49, 817–818.
116. Prattes J et al. (2016). Point of care testing for the diagnosis of fungal infections: are we there yet? *Current Fungal Infection Reports* 10, 43–50.
117. Agarwal R et al. (2015). Performance of serum galactomannan in patients with allergic bronchopulmonary aspergillosis. *Mycoses* 58, 408–412.
118. de Azevedo PZ et al. (2015). Evaluation of the double agar gel immunodiffusion test and of the enzyme-linked immunosorbent assay in the diagnosis and follow-up of patients with chronic pulmonary aspergillosis. *PLoS ONE* 10, e0134841.
119. Bellanger AP et al. (2015). Combining *Aspergillus* mitochondrial and ribosomal QPCR, in addition to galactomannan assay, for early diagnosis of invasive aspergillosis in hematology patients. *Medical Mycology* 53, 760–764.
120. Gorton RL et al. (2015). Improved standardization of the Bio-Rad Platelia *Aspergillus* galactomannan antigen sandwich enzyme immunoassay using the DS2 (Dy nex) enzyme-linked immunosorbent assay (ELISA) processing system. *Journal of Clinical Microbiology* 53, 2072–2078.
121. Guigue N et al. (2015). Importance of operational factors in the reproducibility of *Aspergillus* galactomannan enzyme immune assay. *PLoS ONE* 10, e0124044.
122. Mikulska M et al. (2015). Non-cultural methods for the diagnosis of invasive fungal disease. *Expert Review of Anti-Infective Therapy* 13, 103–117.
123. Roiz MP et al. (2015). Repeating the Platelia™ *Aspergillus* test in samples positive for serum galactomannan: is it necessary? *Revista Iberoamericana de Micología* 32, 204–207.
124. Wang Y-F et al. (2015). Serological surveillance for *Penicillium marneffei* infection in HIV-infected patients during 2004-2011 in Guangzhou, China. *Clinical Microbiology and Infection* 21, 484–489.
125. Zheng J et al. (2015). A clinical study of acquired immunodeficiency syndrome associated *Penicillium marneffei* infection from a non-endemic area in China. *PLoS ONE* 10, e0130376.
126. Badiie P et al. (2014). Evaluation of noninvasive methods for the diagnosis of fungal endocarditis. *Medical Mycology* 52, 528–534.
127. Gazzoni FF et al. (2014). High-resolution computed tomographic findings of *Aspergillus* infection in lung transplant patients. *European Journal of Radiology* 83, 79–83.
128. Griffin AT and Hanson KE (2014). Update on fungal diagnostics. *Current Infectious Disease Reports* 16, 415.
129. Lamoth F and Alexander BD (2014). Nonmolecular methods for the diagnosis of respiratory fungal infections. *Clinics in Laboratory Medicine* 34, 315–336.
130. Lin J-C et al. (2014). Evaluation of galactomannan enzyme immunoassay and quantitative real-time PCR for the diagnosis of invasive pulmonary aspergillosis in a rat model. *Journal of Microbiology and Biotechnology* 24, 1044–1050.
131. Nucci M et al. (2014). Earlier diagnosis of invasive fusariosis with *Aspergillus* serum galactomannan testing. *PLoS ONE* 9, e87784.
132. Sulahian A et al. (2014). Use and limits of (1-3)- β -D-glucan assay (Fungitell), compared to galactomannan determination (Platelia *Aspergillus*), for diagnosis of invasive aspergillosis. *Journal of Clinical Microbiology* 52, 2328–2333.
133. Vergidis P et al. (2014). Reduction in false-positive *Aspergillus* serum galactomannan enzyme immunoassay results associated with use of piperacillin-tazobactam in the United States. *Journal of Clinical Microbiology* 52, 2199–2201.
134. Virginio ED et al. (2014). Immunoproteome of *Aspergillus fumigatus* using sera of patients with invasive aspergillosis. *International Journal of Molecular Sciences* 15, 14505–14530.
135. Wang L et al. (2014). Retrospective comparison of nucleic acid sequence-based amplification, real-time PCR, and galactomannan test for diagnosis of invasive aspergillosis. *Journal of Molecular Diagnostics* 16, 584–590.
136. Held J et al. (2013). Comparison of a novel *Aspergillus* lateral-flow device and the Platelia® galactomannan assay for the diagnosis of invasive aspergillosis following haematopoietic stem cell transplantation. *Infection* 41, 1163–1169.
137. Lackner M and Lass-Flörl C (2013). Up-date on diagnostic strategies of invasive aspergillosis. *Current Pharmaceutical Design* 19, 3595–3614.
138. Lindsley MD (2013). The future of fungal serology. *Current Fungal Infection Reports* 7, 161–170.
139. Morrissey CO et al. (2013). Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial. *The Lancet Infectious Diseases* 13, 519–528.
140. Nabili M et al. (2013). Detection of invasive aspergillosis in bone marrow transplant recipients using real-time PCR. *Journal of Global Infectious Diseases* 5, 68–75.
141. Richaud C et al. (2013). Fungal infections associated with travel. *Current Fungal Infection Reports* 7, 311–319.
142. Schwarzinger M et al. (2013). Performance of serum biomarkers for the early detection of invasive aspergillosis in febrile, neutropenic patients: a multi-state model. *PLoS ONE* 8, e65776.

143. Steinbach WJ (2013). Are we there yet? Recent progress in the molecular diagnosis and novel antifungal targeting of *Aspergillus fumigatus* and invasive aspergillosis. *PLoS Pathogens* 9, e1003642.
144. Trabelsi H et al. (2013). Invasive fungal infections in renal transplant recipients: about 11 cases. *Journal de Mycologie Médicale* 23, 255–260.
145. Badiie P et al. (2012). Diagnostic potential of nested PCR, galactomannan EIA, and beta-D-glucan for invasive aspergillosis in pediatric patients. *Journal of Infection in Developing Countries* 6, 352–357.
146. Bizzini A et al. (2012). Response to: Lack of intra-laboratory reproducibility in using Platelia *Aspergillus* enzyme immunoassay test for detection of *Aspergillus* galactomannan antigen. *Transplant Infectious Disease* 14, 218–219.
147. D'Haese J et al. (2012). Detection of galactomannan in bronchoalveolar lavage fluid samples of patients at risk for invasive pulmonary aspergillosis: analytical and clinical validity. *Journal of Clinical Microbiology* 50, 1258–1263.
148. Fontana C et al. (2012). (1-3)- β -D-glucan vs galactomannan antigen in diagnosing invasive fungal infections (IFIs). *Open Microbiology Journal* 6, 70–73.
149. Izumikawa K et al. (2012). Bronchoalveolar lavage galactomannan for the diagnosis of chronic pulmonary aspergillosis. *Medical Mycology* 87, 811–817.
150. Metan G et al. (2012). Does ampicillin-sulbactam cause false positivity of (1,3)-beta-D-glucan assay? A prospective evaluation of 15 patients without invasive fungal infections. *Mycoses* 55, 366–371.
151. Nabili M et al. (2012). [Evaluation of galactomannan assay in serum for detection of invasive aspergillosis in patients with hematologic malignancies and bone marrow transplant recipients]. *Journal of Mazandaran University of Medical Sciences* 22, 9–19. (Persian)
152. Oren I et al. (2012). Lack of intra-laboratory reproducibility in using Platelia *Aspergillus* enzyme immunoassay test for detection of *Aspergillus* galactomannan antigen. *Transplant Infectious Disease* 14, 107–109.
153. Stopiglia CDO et al. (2012). Standardization and characterization of antigens for the diagnosis of aspergillosis. *Canadian Journal of Microbiology* 58, 455–462.
154. Tănase AD et al. (2012). Using the galactomannan antigen assay in the diagnosis of invasive aspergillosis after hematopoietic stem cell transplantation. *Romanian Journal of Morphology and Embryology* 53, 379–382.
155. Thornton C et al. (2012). Detection of invasive pulmonary aspergillosis in haematological malignancy patients by using lateral-flow technology. *Journal of visualized experiments: JoVE*, 3721.
156. Van Der Veer J et al. (2012). Cross-reactivity in the Platelia™ *Aspergillus* enzyme immunoassay caused by blastomycosis. *Medical Mycology* 50, 396–398.
157. Warren TA et al. (2012). Serum galactomannan in cystic fibrosis patients colonized with *Aspergillus* species. *Medical Mycology* 50, 658–660.
158. Aydoğan S et al. (2010). [Comparison of glucan and galactomannan tests with real-time PCR for diagnosis of invasive aspergillosis in a neutropenic rat model]. *Mikrobiyoloji bülteni* 44, 441–452. (Turkish)
159. Gao X et al. (2010). Invasive pulmonary aspergillosis in acute exacerbation of chronic obstructive pulmonary disease and the diagnostic value of combined serological tests. *Annals of Saudi Medicine* 30, 193–197.
160. Metan G et al. (2010). The interaction between piperacillin/tazobactam and assays for *Aspergillus* galactomannan and 1,3-beta-d-glucan in patients without risk factors for invasive fungal infections. *Infection* 38, 217–221.
161. Millon L et al. (2010). False-positive *Aspergillus* real-time PCR assay due to a nutritional supplement in a bone marrow transplant recipient with GVH disease. *Medical Mycology* 48, 661–664.
162. Paugam A et al. (2010). Diagnosis of invasive pulmonary aspergillosis: value of bronchoalveolar lavage galactomannan for immunocompromised patients. *Pathologie Biologie* 58, 100–103.
163. Racil Z et al. (2010). Mucositis does not lead to false-positivity of the Platelia *Aspergillus* enzyme-linked immunosorbent assay. *European Journal of Clinical Microbiology and Infectious Diseases* 29, 851–855.
164. Thornton CR (2010). Detection of invasive aspergillosis. *Advances in Applied Microbiology* 70, 187–216.
165. Kitasato Y et al. (2009). Comparison of *Aspergillus* galactomannan antigen testing with a new cut-off index and *Aspergillus* precipitating antibody testing for the diagnosis of chronic pulmonary aspergillosis. *Respirology* 14, 701–708.
166. Luong M et al. (2009). *Aspergillus* galactomannan antigen in bronchoalveolar lavage (BAL) from haematology oncology patients: time for a change in index cut-off value. *International Journal of Antimicrobial Agents* 34, S15–S16.
167. Maertens J et al. (2009). Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases. *Clinical Infectious Diseases* 49, 1688–1693.
168. Sun Q-X et al. (2009). [Utility of serum galactomannan in diagnosis of invasive fungal infection in hematologic malignancy]. *Chinese Journal of Infection and Chemotherapy* 9, 140–142. (Chinese)

169. Xu M-Z et al. (2009). [Utility of serum galactomannan antigen for diagnosis and follow-up of invasive aspergillosis in hematological patients]. *Chinese Journal of Infection and Chemotherapy* 9, 233–236. (Chinese)
170. Yao JF et al. (2009). [A preliminary investigation on early diagnosis of invasive aspergillosis in patients with blood diseases by using circulating galactomannan test]. *Zhongguo Shi Yan Xue Ye Xue Za Zhi* 17, 765–769. (Chinese)
171. Yao JF et al. (2009). [Circulating galactomannan screening for early diagnosis and treatment of invasive aspergillosis]. *Zhongguo Shi Yan Xue Ye Xue Za Zhi* 30, 592–595. (Chinese)
172. Hao W et al. (2008). Well-characterized monoclonal antibodies against cell wall antigen of *Aspergillus* species improve immunoassay specificity and sensitivity. *Clinical and Vaccine Immunology* 15, 194–202.
173. Husain S et al. (2008). Performance characteristics of the Platelia *Aspergillus* enzyme immunoassay for detection of *Aspergillus* galactomannan antigen in bronchoalveolar lavage fluid. *Clinical and Vaccine Immunology* 15, 1760–1763.
174. Mennink-Kersten MASH et al. (2008). Improved detection of circulating *Aspergillus* antigen by use of a modified pretreatment procedure. *Journal of Clinical Microbiology* 46, 1391–1397.
175. Penack O et al. (2008). *Aspergillus* galactomannan testing in patients with long-term neutropenia: implications for clinical management. *Annals of Oncology* 19, 984–989.
176. Penack O et al. (2008). False-positive *Aspergillus* antigen testing due to application of piperacillin/tazobactam—is it still an issue? *Diagnostic Microbiology and Infectious Disease* 60, 117–120.
177. Zandijk E et al. (2008). False-positive results by the Platelia *Aspergillus* galactomannan antigen test for patients treated with amoxicillin-clavulanate. *Clinical and Vaccine Immunology* 15, 1132–1133.
178. Ahmad S et al. (2007). Diagnostic value of DNA, (1-3)- β -D-glucan, and galactomannan detection in serum and bronchoalveolar lavage of mice experimentally infected with *Aspergillus terreus*. *Diagnostic Microbiology and Infectious Disease* 59, 165–171.
179. De Jesus M et al. (2007). Galactoxylomannan does not exhibit cross-reactivity in the Platelia *Aspergillus* enzyme immunoassay. *Clinical and Vaccine Immunology* 14, 624–627.
180. Hage CA et al. (2007). Plasmalyte as a cause of false-positive results for *Aspergillus* galactomannan in bronchoalveolar lavage fluid. *Journal of Clinical Microbiology* 45, 676–677.
181. Huang YT et al. (2007). Detection of circulating galactomannan in serum samples for diagnosis of *Penicillium marneffei* infection and cryptococcosis among patients infected with human immunodeficiency virus. *Journal of Clinical Microbiology* 45, 2858–2862.
182. Husain S et al. (2007). *Aspergillus* galactomannan antigen in the bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in lung transplant recipients. *Transplantation* 83, 1330–1336.
183. Lai CC et al. (2007). Assessment of Platelia *Aspergillus* enzyme immunoassay for the diagnosis of invasive aspergillosis. *Journal of Microbiology, Immunology and Infection* 40, 148–153.
184. Lim ZY et al. (2007). False positive results of galactomannan ELISA assay in haemato-oncology patients: a single centre experience. *Journal of Infection* 55, 201–202.
185. Maertens J et al. (2007). Optimization of the cutoff value for the *Aspergillus* double-sandwich enzyme immunoassay. *Clinical Infectious Diseases* 44, 1329–1336.
186. Nataloni S et al. (2007). Successful early voriconazole treatment of *Aspergillus* infection in two non immunocompromised patients in Intensive Care Unit. *Minerva Anestesiologica* 73, 371–375.
187. Ranque S et al. (2007). Platelia *Aspergillus* assay for diagnosis of disseminated histoplasmosis. *European Journal of Clinical Microbiology and Infectious Diseases* 26, 941–943.
188. Wheat LJ et al. (2007). Histoplasmosis-associated cross-reactivity in the Bio-Rad Platelia *Aspergillus* enzyme immunoassay. *Clinical and Vaccine Immunology* 14, 638–640.
189. Woods G et al. (2007). Serum *Aspergillus* galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: a study of 56 patients with hematologic cancer. *Cancer* 110, 830–834.
190. Yücesoy M and Ergon MC (2007). [Investigation of *Aspergillus* galactomannan levels in antimicrobial agents]. *Mikrobiyoloji bülteni* 41, 565–570. (Turkish)
191. Alexander BD and Pfaller MA (2006). Contemporary tools for the diagnosis and management of invasive mycoses. *Clinical Infectious Diseases* 43, S15–S27.
192. Aubry A et al. (2006). Occurrence and kinetics of false-positive *Aspergillus* galactomannan test results following treatment with beta-lactam antibiotics in patients with hematological disorders. *Journal of Clinical Microbiology* 44, 389–394.
193. Maertens J et al. (2006). Defining a case of invasive aspergillosis by serum galactomannan. *Medical Mycology* 44, 173–178.
194. Mennink-Kersten MASH et al. (2006). *In vitro* release by *Aspergillus fumigatus* of galactofuranose antigens, 1,3-beta-D-glucan, and DNA, surrogate markers used for diagnosis of invasive aspergillosis. *Journal of Clinical Microbiology* 44, 1711–1718.
195. Rex JH (2006). Galactomannan and the diagnosis of invasive aspergillosis. *Clinical Infectious Diseases* 42, 1428–1430.

196. Roilides E (2006). Early diagnosis of invasive aspergillosis in infants and children. *Medical Mycology* 44, 199–205.
197. Verweij PE and Mennink-Kersten MASH (2006). Issues with galactomannan testing. *Medical Mycology* 44, 179–183.
198. Allan EK et al. (2005). Poor performance of galactomannan and mannan sandwich enzyme-linked immunosorbent assays in the diagnosis of invasive fungal infection. *British Journal of Haematology* 128, 578–579.
199. Bart-Delabesse E et al. (2005). Detection of *Aspergillus* galactomannan antigenemia to determine biological and clinical implications of beta-lactam treatments. *Journal of Clinical Microbiology* 43, 5214–5220.
200. Hope WW et al. (2005). Laboratory diagnosis of invasive aspergillosis. *Lancet Infectious Diseases* 5, 609–622.
201. Ide L et al. (2005). A case of *Aspergillus fumigatus* peritonitis in a patient undergoing continuous ambulatory peritoneal dialysis (CAPD): diagnostic and therapeutic challenges. *Journal of Clinical Pathology* 58, 559.
202. Joseph Wheat L (2005). Galactomannan antigenemia detection for diagnosis of invasive aspergillosis, part II. *Clinical Microbiology Newsletter* 27, 59–63.
203. Labadaridis I et al. (2005). Chitotriosidase in neonates with fungal and bacterial infections. *Archives of Disease in Childhood: Fetal and Neonatal Edition* 90, F531–F532.
204. Pazos C et al. (2005). [Contribution of (1→3)-beta-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan]. *Journal of Clinical Microbiology* 43, 299–305. (Spanish)
205. Pereira CN et al. (2005). The contribution of galactomannan detection in the diagnosis of invasive aspergillosis in bone marrow transplant recipients. *Mycopathologia* 159, 487–493.
206. Scotter JM et al. (2005). Comparison of PCR-ELISA and galactomannan detection for the diagnosis of invasive aspergillosis. *Pathology* 37, 246–253.
207. Wheat LJ (2005). Galactomannan antigenemia detection for diagnosis of invasive aspergillosis, part I. *Clinical Microbiology Newsletter* 27, 51–57.
208. Zaas AK and Alexander BD (2005). Galactomannan and advances in fungal diagnostics. *Current Opinion in Organ Transplantation* 10, 307–311.
209. Husain S et al. (2004). Prospective assessment of *Platelia Aspergillus* galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant recipients. *American Journal of Transplantation* 4, 796–802.
210. Klont RR et al. (2004). Utility of *Aspergillus* antigen detection in specimens other than serum specimens. *Clinical Infectious Diseases* 39, 1467–1474.
211. Kwak EJ et al. (2004). Efficacy of galactomannan antigen in the *Platelia Aspergillus* enzyme immunoassay for diagnosis of invasive aspergillosis in liver transplant recipients. *Journal of Clinical Microbiology* 42, 435–438.
212. Maertens J et al. (2004). Prospective clinical evaluation of lower cut-offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients. *British Journal of Haematology* 126, 852–860.
213. Mennink-Kersten MASH et al. (2004). Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. *Lancet Infectious Diseases* 4, 349–357.
214. Singh N et al. (2004). Reactivity of *Platelia Aspergillus* galactomannan antigen with piperacillin-tazobactam: clinical implications based on achievable concentrations in serum. *Antimicrobial Agents and Chemotherapy* 48, 1989–1992.
215. Willinger B (2004). [Antigen detection in invasive aspergillosis and candidosis: the Austrian experience]. *Mycoses, Supplement* 47, 48–54. (German)
216. Jarque I et al. (2003). [Value of *Aspergillus* galactomannan antigen detection in the diagnosis and follow-up of invasive aspergillosis in hematological patients]. *Revista Iberoamericana de Micologia* 20, 116–118. (Spanish)
217. Lombardi G et al. (2003). Multicenter evaluation of an enzyme immunoassay (*Platelia Aspergillus*) for the detection of *Aspergillus* antigen in serum. *Mycopathologia* 155, 129–133.
218. Meletiadiis J et al. (2003). Evaluation of a polymerase chain reaction reverse hybridization line probe assay for the detection and identification of medically important fungi in bronchoalveolar lavage fluids. *Medical Mycology* 41, 65–74.
219. Moragues MD et al. (2003). [Usefulness of galactomannan detection in the diagnosis and follow-up of hematological patients with invasive aspergillosis]. *Revista Iberoamericana de Micologia* 20, 103–110. (Spanish)
220. del Palacio A et al. (2003). [Laboratory diagnosis of invasive aspergillosis]. *Revista Iberoamericana de Micologia* 20, 90–98. (Spanish)
221. del Palacio A et al. (2003). [Invasive aspergillosis]. *Revista Iberoamericana de Micologia* 20, 77–78. (Spanish)
222. Pazos C and del Palacio A (2003). [Early diagnosis of invasive aspergillosis in neutropenic patients with bi-weekly serial screening of circulating galactomannan by *Platelia Aspergillus*]. *Revista Iberoamericana de Micologia* 20, 99–102. (Spanish)
223. Pinel C et al. (2003). Detection of circulating *Aspergillus fumigatus* galactomannan: value and limits of the *Platelia* test for diagnosing invasive aspergillosis. *Journal of Clinical Microbiology* 41, 2184–2186.

224. Rovira Tarrats M and De La Bellacasa JP (2003). [*Aspergillus* galactomannan detection in allogeneic hematopoietic cell transplantation]. *Revista Iberoamericana de Micología* 20, 111–115. (Spanish)
225. Sulahian A et al. (2003). False positive test for *Aspergillus* antigenemia related to concomitant administration of piperacillin and tazobactam. *New England Journal of Medicine* 349, 2366–2367.
226. Wheat LJ (2003). Rapid diagnosis of invasive aspergillosis by antigen detection. *Transplant Infectious Disease* 5, 158–166.
227. Centeno-Lima S et al. (2002). Follow-up of anti-*Aspergillus* IgG and IgA antibodies in bone marrow transplanted patients with invasive aspergillosis. *Journal of Clinical Laboratory Analysis* 16, 156–162.
228. Doermann F et al. (2002). [Evaluation of *Aspergillus* antigen detection in sera by ELISA for diagnosis of invasive aspergillosis in a hematological unit]. *Journal de Mycologie Médicale* 12, 131–135. (French)
229. Cuenca-Estrella M and Rodríguez-Tudela JL (2001). Critical assessment of issues in the diagnosis of invasive aspergillosis. *Clinical Microbiology and Infection* 7, 32–37.
230. Fortun J et al. (2001). *Aspergillus* antigenemia sandwich-enzyme immunoassay test as a serodiagnostic method for invasive aspergillosis in liver transplant recipients. *Transplantation* 71, 145–149.
231. Hamaki T et al. (2001). False-positive results of *Aspergillus* enzyme-linked immunosorbent assay in a patient with chronic graft-versus-host disease after allogeneic bone marrow transplantation. *Bone Marrow Transplantation* 28, 633–634.
232. Siemann M and Koch-Dörfler M (2001). The *Platelia Aspergillus* ELISA in diagnosis of invasive pulmonary aspergillosis (IPA). *Mycoses* 44, 266–272.
233. Sulahian A et al. (2001). Value of antigen detection using an enzyme immunoassay in the diagnosis and prediction of invasive aspergillosis in two adult and pediatric hematology units during a 4-year prospective study. *Cancer* 91, 311–318.
234. Tollemar J et al. (2001). Role of early diagnosis and aggressive surgery in the management of invasive pulmonary aspergillosis in neutropenic patients. *Clinical Microbiology and Infection* 7, 54–61.
235. Buchheidt D et al. (2000). Systemic infections with *Candida* sp. and *Aspergillus* sp. in immunocompromised patients with hematological malignancies: current serological and molecular diagnostic methods. *Chemotherapy* 46, 219–228.
236. Machetti M et al. (2000). Antigen detection in the diagnosis and management of a patient with probable cerebral aspergillosis treated with voriconazole. *Transplant Infectious Disease* 2, 140–144.
237. Salonen J et al. (2000). *Aspergillus* antigen in serum, urine and bronchoalveolar lavage specimens of neutropenic patients in relation to clinical outcome. *Scandinavian Journal of Infectious Diseases* 32, 485–490.
238. Verweij PE et al. (2000). Failure to detect circulating *Aspergillus* markers in a patient with chronic granulomatous disease and invasive aspergillosis. *Journal of Clinical Microbiology* 38, 3900–3901.
239. Williamson EC et al. (2000). *Aspergillus* antigen testing in bone marrow transplant recipients. *Journal of Clinical Pathology* 53, 362–366.
240. Costes B et al. (1999). Lack of evidence of heterozygosity for cystic fibrosis as a risk factor for invasive aspergillosis in haematological patients. *European Journal of Clinical Microbiology and Infectious Diseases* 18, 677–678.
241. Kawamura S et al. (1999). Comparison between PCR and detection of antigen in sera for diagnosis of pulmonary aspergillosis. *Journal of Clinical Microbiology* 37, 218–220.
242. Letscher-Bru V et al. (1998). [*Aspergillus* galactomannan antigen detection with *Platelia Aspergillus*: multiple positive antigenemia without *Aspergillus* infection]. *Journal de Mycologie Médicale* 8, 112–113. (French)
243. Machetti M et al. (1998). Comparison of an enzyme immunoassay and a latex agglutination system for the diagnosis of invasive aspergillosis in bone marrow transplant recipients. *Bone Marrow Transplantation* 21, 917–921.
244. Siemann M et al. (1998). False-positive results in premature infants with the *Platelia Aspergillus* sandwich enzyme-linked immunosorbent assay. *Mycoses* 41, 373–377.
245. Verweij PE et al. (1998). Detection of antigen in sera of patients with invasive aspergillosis: intra- and interlaboratory reproducibility. *Journal of Clinical Microbiology* 36, 1612–1616.

Posters

246. Aerts R et al. (2022). QuickGM *Aspergillus* galactomannan Ag lateral flow assay as a practical aid to diagnose invasive aspergillosis in high-risk hematology patients. *Medical Mycology* 60, 244–245. P412. <http://dx.doi.org/10.1093/mmy/myac072.P412>
247. Padaki P et al. (2022). A study to compare detection of *Aspergillus* galactomannan in patients with clinically suspected invasive aspergillosis using the Lateral Flow Assay (LFA) in comparison with Enzyme Linked Immunosorbent Assay (ELISA) and identification of new risk factors as per BM-AspICU criteria. *Medical Mycology* 60, 259–260. P436. <http://dx.doi.org/10.1093/mmy/myac072.P436>

248. Singh S et al. (2022). Evaluation of fungal serum biomarkers in the diagnosis and for monitoring patients with post tuberculosis chronic pulmonary aspergillosis. *Medical Mycology* 60, 242. P408. <http://dx.doi.org/10.1093/mmy/myac072.P408>
249. Ono A et al. (2020). [The clinical and immunological features of NMO patients with onset over 80 years old]. *Clinical Neurology* 60, S371. https://doi.org/10.5692/clinicalneuro.60_supplement_S371 (Japanese)
250. Farooqi JQ et al. (2017). Utility of (1-3)- β -D-glucan and galactomannan for invasive fungal infections at Aga Khan University Clinical Laboratory, Karachi. *Mycoses* 60, 120–121. P002. <https://doi.org/10.1111/myc.12674>.
251. Simon M et al. (2017). Pretreatment of respiratory specimens with Liquillizer™ does not impair the detection of galactomannan antigen in contrast to other mucolytic agents. *Mycoses* 60, 25–26. P09. <http://dx.doi.org/10.1111/myc.12659>
252. Tryliska T et al. (2017). Galactomannan antigen detection for the diagnostics and monitoring of the efficacy of invasive aspergillosis treatment: experience with the method in pediatric patients. *Clinical Chemistry and Laboratory Medicine* 55, S929. W121. <http://dx.doi.org/10.1515/cclm-2017-5026>
253. Yu W-L (2017). Epidemiological correlation of PM2.5 with invasive pulmonary aspergillosis in severe influenza patients. *International Journal of Antimicrobial Agents* 50, Supplement 2, S193–S194. PS 335. [https://doi.org/10.1016/S0924-8579\(17\)30423-5](https://doi.org/10.1016/S0924-8579(17)30423-5)
254. Findik D et al. (2015). Combination of galactomannan detection and computed tomographic findings for diagnosis of invasive pulmonary aspergillosis. *Mycoses* 58, 97–98. P128. <http://dx.doi.org/10.1111/myc.12380>
255. Ignatyeva SM et al. (2015). Galactomannan determination in biological samples of non-hematological patients with invasive aspergillosis caused by different *Aspergillus* spp. *Mycoses* 58, 107. P147. <http://dx.doi.org/10.1111/myc.12380>
256. Tran VH et al. (2015). Survey of serum *Aspergillus* antigen in patients undergoing chemotherapy for acute myeloid leukemia or allogeneic hematopoietic stem cell transplantation: role in predicting invasive aspergillosis and in modifying the therapeutic strategy. *Blood* 126, 3428. <https://doi.org/10.1182/blood.V126.23.3428.3428>
257. Binder U et al. (2013). Influence of hypoxia on antifungal susceptibility, sterol pattern and biomarker release of *Aspergillus* spp. *Mycoses* 56, 62. P014. <http://dx.doi.org/10.1111/myc.12124>
258. Golas M et al. (2013). Quantitative galactomannan detection in comparison to real-time PCR method in diagnosing invasive aspergillosis. *Mycoses* 56, 74–75. P052. <http://dx.doi.org/10.1111/myc.12124>
259. Keceli S et al. (2013). Correlation of galactomannan antigen levels with neutrophil counts and iNOS activity in hematological patients at high risk for invasive aspergillosis. *Mycoses* 56, 116. P172. <http://dx.doi.org/10.1111/myc.12124>
260. Persat F (2013). New *Aspergillus* antigen detection LFD kit for the IPA diagnostic: what results with positive and negative galactomannan ELISA sera? *Mycoses* 56, 85–86. P077. <http://dx.doi.org/10.1111/myc.12124>
261. Beck J et al. (2012). Characterization of chitosanase B of *Aspergillus fumigatus* and evaluation of its potential use as an antigen in serological diagnostics. *Mycoses* 55, 182. P281. <http://dx.doi.org/10.1111/j.1439-0507.2012.02206.x>
262. Delfino E et al. (2012). Sputum galactomannan in cystic fibrosis patients colonized with *Aspergillus fumigatus*. *Pediatric Pulmonology* 47, 341. P330. <http://dx.doi.org/10.1002/ppul.22682>
263. Persat F et al. (2012). External quality assessment scheme and interlaboratory proficiency testing for *Aspergillus* galactomannan ELISA. *Mycoses* 55, 272. P562. <http://dx.doi.org/10.1111/j.1439-0507.2012.02206.x>
264. Rath PM et al. (2012). Detection of *Aspergillus fumigatus*-DNA in blood by a commercially available multiplex-PCR. *Mycoses* 55, 295. P637. <http://dx.doi.org/10.1111/j.1439-0507.2012.02206.x>
265. Yebra E et al. (2012). Utility of galactomannan enzyme immunoassay, (1-3) β -D-glucan assay and anti-*Candida albicans* germ tube antibodies in invasive fungal disease in patients with hematologic malignancies. *Mycoses* 55, 288–289. P613. <http://dx.doi.org/10.1111/j.1439-0507.2012.02206.x>
266. Berry L et al. (2011). The use of galactomannan detection in urine samples from haemato-oncology patients at high risk of invasive aspergillosis. *Clinical Microbiology and Infection* 17, S632–S633. P355. <http://dx.doi.org/10.1111/j.1469-0691.2011.03558.x>
267. Khan Z et al. (2011). Development of an inhalation model of invasive pulmonary aspergillosis by *Aspergillus fumigatus* for evaluating the efficacy of detection of non-invasive markers for early diagnosis of infection. *Clinical Microbiology and Infection* 17, S568. P1939. <http://dx.doi.org/10.1111/j.1469-0691.2011.03558.x>
268. Nawrot U et al. (2011). Diagnostic pitfalls in *Aspergillus* galactomannan blood testing in the diagnosis of invasive fungal diseases in pediatric patients after hematopoietic stem cell transplantation. *Mycoses* 54, 102–103. <http://dx.doi.org/10.1111/j.1439-0507.2011.02092.x>
269. Roselló E et al. (2011). Evaluation of MycAssay™ *Aspergillus* molecular diagnostic test and automated EZ1 DNA extraction for detecting *Aspergillus* spp. DNA in bronchoalveolar samples of patients with risk factors for pulmonary invasive aspergillosis. *Clinical Microbiology and Infection* 17, S568–S569. P1942. <http://dx.doi.org/10.1111/j.1469-0691.2011.03558.x>

270. Srebro D et al. (2011). Diagnosis of invasive fungal infection by detection of early laboratory biomarkers in a child with anemia aplastica. *Mycoses* 54, 103. <http://dx.doi.org/10.1111/j.1439-0507.2011.02092.x>
271. Sulahian A et al. (2011). Evaluation of the (1→3) β-D glucan assay (Fungitell™) in comparison with Platelia™ *Aspergillus* for the follow-up of invasive aspergillosis under treatment. *Mycoses* 54, 87. <http://dx.doi.org/10.1111/j.1439-0507.2011.02092.x>
272. Virginia R et al. (2011). Galactomannan determination in children: is there a real influence of nutrition? *Mycoses* 54, 88–89. <http://dx.doi.org/10.1111/j.1439-0507.2011.02092.x>
273. Bournoux ME et al. (2010). Saccharose-stabilized intravenous immune globulin as a cause of false-positive *Aspergillus* galactomannan assay in patients. *Clinical Microbiology and Infection* 16, S518. P1759. <http://dx.doi.org/10.1111/j.1469-0691.2010.03239.x>
274. Banon R et al. (2009). Evaluation of serum *Aspergillus* galactomannan in haematological patients. *Clinical Microbiology and Infection* 15, S234. P907. <http://dx.doi.org/10.1111/j.1469-0691.2009.02858.x>
275. Tsagarakis N et al. (2009). Anti-*Aspergillus* antibodies and galactomannan antigen detection for serodiagnosis of aspergillosis. *Clinical Microbiology and Infection* 15, S234. P905. <http://dx.doi.org/10.1111/j.1469-0691.2009.02858.x>

Bio-Rad is a trademark of Bio-Rad Laboratories, Inc.

Platelia is a trademark of Bio-Rad Europe GmbH in certain jurisdictions.

All trademarks used herein are the property of their respective owner.

BIO-RAD

**Bio-Rad
Laboratories, Inc.**

Clinical
Diagnostics Group

Website www.bio-rad.com/diagnostics **Australia** +61 (2) 9914 2800 **Austria** +43 (0) 1 877 89 01 9 **Belgium** +32 (0) 3 710 53 00 **Brazil** +55 11 3065 7550 **Canada** +1 514 334 4372 **China** +86 21 6169 8500 **Czech Republic** +420 241 431 660 **Denmark** +45 44 52 10 00 **Finland** +358 9 804 22 00 **France** +33 (0) 1 47 95 60 00 **Germany** +49 (0) 89 31884 393 **Greece** +30 210 7774396 **Hong Kong** +85 2 2789 3300 **Hungary** +36 1 459 6190 **India** +91 124 4029300 **Israel** +972 03 963 6025 **Italy** +39 024 94 86 600 **Japan** +81 3 6361 7070 **Korea** +82 080 007 7373 **Mexico** +52 (55) 5488 7670 **The Netherlands** +31 (0) 318 540 666 **New Zealand** +64 (9) 415 2280 **Norway** +47 23 38 41 30 **Poland** +48 22 331 99 99 **Portugal** +351 21 47 27 700 **Russia** +7 (495) 721-14-04 **Singapore** +65 6415 3170 **South Africa** +27 11 442 8508 **Spain** +34 91 490 6580 **Sweden** +46 844 98053 **Switzerland** +41 (0) 61 717 9555 **Taiwan** +886 (2) 2578-7189 **Thailand** (662) 651 8311 **United Kingdom** +44 (0) 1923 471301